Sign Out
Treatment of osteolytic, osteoblastic and mixed bone metastases of solid tumors and osteolytic lesions of multiple myeloma, in conjunction with standard antineoplastic therapy.
Reduction of bone damage in patients with advanced malignancies involving bone.
Treatment of hypercalcemia of malignancy (HCM) defined as albumin-corrected serum calcium (cCa) ≥12 mg/dL (3 mmol/L).
